A new VIP summary is available for CYP2C8, a member of the cytochrome P450 family of drug metabolizing
enzymes. CYP2C8 accounts for 7% of CYP content in the liver, and is expressed to
a lesser extent in the kidney, adrenal gland, mammary gland, brain,
ovary, uterus, and duodenum. CYP2C8 plays a major role in the metabolism of many commonly used drugs
[Article:15900280]. Several CYP2C8 SNPs have functional consequences [Article: 20459297] and have been associated with variability in CYP2C8-mediated metabolism and altered disposition and response for many commonly used drugs such as repaglinide, rosiglitazone, pioglitazone,paclitaxel, bisphosphonates, amiodarone and amodiaquine [Articles:12429347, 11668219, 17361129, 23536207, 11767116, 12530467, 18769365]. As a
result, CYP2C8 has emerged as a significant pharmacogene.
For more information on this VIP gene and its variants see the VIP tab for CYP2C8.
For all VIP gene summaries on pharmgkb, see here.
